Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN Japan OAD Combination
NCT02207374Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02207374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207374.